Amalgamated Bank Purchases 271 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Amalgamated Bank boosted its position in Charles River Laboratories International, Inc. (NYSE:CRLGet Rating) by 1.4% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,054 shares of the medical research company’s stock after buying an additional 271 shares during the period. Amalgamated Bank’s holdings in Charles River Laboratories International were worth $5,411,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its holdings in Charles River Laboratories International by 8.5% during the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 28,092 shares of the medical research company’s stock worth $7,977,000 after purchasing an additional 2,197 shares in the last quarter. Strs Ohio boosted its stake in shares of Charles River Laboratories International by 11.5% in the 1st quarter. Strs Ohio now owns 151,994 shares of the medical research company’s stock worth $43,161,000 after buying an additional 15,702 shares during the last quarter. Oppenheimer Asset Management Inc. boosted its stake in shares of Charles River Laboratories International by 30.3% in the 1st quarter. Oppenheimer Asset Management Inc. now owns 36,018 shares of the medical research company’s stock worth $10,228,000 after buying an additional 8,367 shares during the last quarter. Avitas Wealth Management LLC purchased a new position in shares of Charles River Laboratories International in the 1st quarter worth approximately $344,000. Finally, Central Bank & Trust Co. boosted its stake in shares of Charles River Laboratories International by 243.4% in the 1st quarter. Central Bank & Trust Co. now owns 17,613 shares of the medical research company’s stock worth $5,001,000 after buying an additional 12,484 shares during the last quarter. 95.20% of the stock is owned by institutional investors.

Charles River Laboratories International Trading Up 0.1 %

Charles River Laboratories International stock opened at $199.85 on Tuesday. The stock has a market cap of $10.16 billion, a P/E ratio of 23.18, a PEG ratio of 1.32 and a beta of 1.35. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.08 and a current ratio of 1.33. Charles River Laboratories International, Inc. has a fifty-two week low of $195.12 and a fifty-two week high of $460.21. The firm’s fifty day moving average price is $219.29 and its 200-day moving average price is $239.05.

Charles River Laboratories International (NYSE:CRLGet Rating) last released its earnings results on Wednesday, August 3rd. The medical research company reported $2.77 EPS for the quarter, beating analysts’ consensus estimates of $2.74 by $0.03. The business had revenue of $973.13 million for the quarter, compared to analysts’ expectations of $995.12 million. Charles River Laboratories International had a return on equity of 21.51% and a net margin of 12.02%. The firm’s revenue was up 6.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.61 earnings per share. Equities research analysts forecast that Charles River Laboratories International, Inc. will post 10.77 earnings per share for the current fiscal year.

Insider Activity at Charles River Laboratories International

In related news, EVP Joseph W. Laplume sold 200 shares of the stock in a transaction on Friday, August 5th. The stock was sold at an average price of $226.13, for a total value of $45,226.00. Following the transaction, the executive vice president now owns 20,766 shares of the company’s stock, valued at $4,695,815.58. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 1.10% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. Morgan Stanley downgraded Charles River Laboratories International from an “overweight” rating to an “equal weight” rating and cut their target price for the stock from $350.00 to $250.00 in a research note on Thursday, August 4th. Guggenheim assumed coverage on Charles River Laboratories International in a research note on Monday, May 23rd. They issued a “neutral” rating on the stock. They noted that the move was a valuation call. Evercore ISI dropped their price objective on Charles River Laboratories International to $260.00 in a research note on Tuesday, August 9th. Wells Fargo & Company dropped their price objective on Charles River Laboratories International from $325.00 to $300.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 16th. Finally, Stephens set a $315.00 price objective on Charles River Laboratories International in a research note on Monday, June 20th. Four investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat, Charles River Laboratories International presently has an average rating of “Moderate Buy” and a consensus target price of $317.67.

Charles River Laboratories International Company Profile

(Get Rating)

Charles River Laboratories International, Inc, a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

Read More

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRLGet Rating).

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.